At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas
In Brief
A Phase 2 clinical trial evaluating Cabozantinib S-malate, Laboratory Biomarker Analysis, and 1 other intervention for Locally Advanced Paraganglioma and 5 related conditions. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This pilot phase II trial studies how well cabozantinib s-malate works in treating patients with pheochromocytomas or paragangliomas that have spread from the primary site to other places in the body and cannot be removed by surgery. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking the growth of new blood vessels necessary for tumor growth.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Ancillary studies